The Journal of Urology · 1993 · 16 citations · 19 references
MedicineMolecular BiologyOncologyGenitourinary OncologyMolecular OncologyProtein EngineeringBladder CancerProtein TargetingTargeted Cancer TherapyTargeted TherapyBioactivity In Vitro TestingBladder Tumor CharacterizationTargetingTherapeutic Targeting Of Fusion Proteins
TP-40 is a hybrid fusion protein produced by recombinant technology and consists of a molecule of transforming growth factor-alpha (TGF-alpha) fused to the Pseudomonas exotoxin PE-40. A panel of human and murine bladder cancer cell lines was found to be universally sensitive in vitro to TP-40 in a clonogenic assay. All lines expressed receptor for epidermal growth factor (EGF), though none demonstrated gene amplification for the EGF receptor. The sensitivity to TP-40 may be blocked by preexposure to EGF. Six human bladder tumors taken directly from patients were all sensitive in vitro to TP-40; these included well-differentiated tumors. TP-40 may prove to be effective as an intravesical agent in bladder cancer via selective targeting to cells that express EGF receptors, as do the majority of human bladder cancers.
19
Molecular Cloning. A Laboratory Manual
EJ Wood · Biochemical Education · 1983 · 30.6K citations
Donald L. Lamm, Brent A. Blumenstein, E. David Crawford et al. · New England Journal of Medicine · 1991 · 617 citations · Full text
C. C. Boring, T. S. Squires, T. Tong · CA A Cancer Journal for Clinicians · 1992 · 533 citations · Full text